HKSE - Delayed Quote HKD
Akeso, Inc. (9926.HK)
As of 10:03 AM GMT+8. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
4,526,253.000
4,526,253.000
837,656.000
225,626.000
--
--
Cost of Revenue
133,248.000
133,248.000
94,117.000
31,259.000
--
--
Gross Profit
4,393,005.000
4,393,005.000
743,539.000
194,367.000
--
--
Operating Expense
2,226,181.000
2,226,181.000
1,965,561.000
1,460,801.000
952,423.000
--
Operating Income
2,166,824.000
2,166,824.000
-1,222,022.000
-1,266,434.000
-952,423.000
--
Net Non Operating Interest Income Expense
32,746.000
32,746.000
-21,318.000
3,884.000
26,518.000
--
Pretax Income
1,942,525.000
1,942,525.000
-1,422,216.000
-1,258,126.000
-1,320,579.000
--
Tax Provision
174.000
174.000
--
--
--
--
Net Income Common Stockholders
2,028,300.000
2,028,300.000
-1,168,393.000
-1,074,933.000
-1,036,374.000
--
Diluted NI Available to Com Stockholders
2,028,300.000
2,028,300.000
-1,168,393.000
-1,074,933.000
-1,036,374.000
--
Basic EPS
2.42
--
-1.42
-1.32
-1.65
-0.37
Diluted EPS
2.42
--
-1.42
-1.32
-1.65
-0.37
Basic Average Shares
837,683.779
--
824,989.858
815,931.798
628,941.610
763,133.176
Diluted Average Shares
837,821.477
--
824,989.858
815,931.798
628,941.610
763,133.176
Rent Expense Supplemental
2,683.000
--
--
--
--
2,038.000
Total Expenses
2,359,429.000
2,359,429.000
2,059,678.000
1,492,060.000
952,423.000
--
Net Income from Continuing & Discontinued Operation
2,028,300.000
2,028,300.000
-1,168,393.000
-1,074,933.000
-1,177,051.000
--
Normalized Income
1,976,198.667
1,976,198.667
-1,174,497.000
-1,083,455.000
-1,184,074.000
--
Interest Income
119,733.000
119,733.000
21,972.000
14,236.000
34,505.000
--
Interest Expense
86,987.000
86,987.000
43,290.000
10,352.000
7,987.000
--
Net Interest Income
32,746.000
32,746.000
-21,318.000
3,884.000
26,518.000
--
EBIT
2,029,512.000
2,029,512.000
-1,378,926.000
-1,247,774.000
-1,312,592.000
--
EBITDA
2,172,280.000
2,172,280.000
-1,273,137.000
-1,189,531.000
-1,290,485.000
--
Reconciled Cost of Revenue
133,248.000
133,248.000
94,117.000
31,259.000
--
--
Reconciled Depreciation
142,768.000
142,768.000
105,789.000
58,243.000
22,107.000
--
Net Income from Continuing Operation Net Minority Interest
2,028,300.000
2,028,300.000
-1,168,393.000
-1,074,933.000
-1,177,051.000
--
Total Unusual Items Excluding Goodwill
52,106.000
52,106.000
6,104.000
8,522.000
7,023.000
--
Total Unusual Items
52,106.000
52,106.000
6,104.000
8,522.000
7,023.000
--
Normalized EBITDA
2,120,174.000
2,120,174.000
-1,279,241.000
-1,198,053.000
-1,297,508.000
--
Tax Rate for Calcs
0.000
0.000
--
--
--
--
Tax Effect of Unusual Items
4.667
4.667
--
--
--
--
12/31/2019 - 4/24/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
1801.HK Innovent Biologics, Inc.
45.550
-0.33%
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
190.500
+0.74%
9969.HK InnoCare Pharma Limited
6.880
-0.43%
6160.HK BeiGene, Ltd.
133.700
+2.22%
9966.HK Alphamab Oncology
3.700
-1.07%
9688.HK Zai Lab Limited
22.250
+3.25%
9995.HK RemeGen Co., Ltd.
14.740
-0.41%
1541.HK ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
5.900
+3.87%
2171.HK CARsgen Therapeutics Holdings Limited
3.990
+1.27%
3759.HK Pharmaron Beijing Co., Ltd.
14.880
+0.95%